Captopril in Severe Childhood Hypertension--reversible Anaemia with High Dosage

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 1986 Apr 1

PMID 3519229

Citations 1

Authors

H A Verhaaren

J Vande Walle

Affiliations

Soon will be listed here.

Abstract

Experience with chronic inhibition of the angiotensin-converting enzyme in children is limited to cases refractory to all other forms of treatment. In reports dealing with the use of captopril (Capoten-R) in children no important side-effects are mentioned. This report describes a 7-year-old boy with severe hypertension secondary to haemolytic uraemic syndrome. Good pressure control was obtained after introduction of captopril. However, under the high initial dosage, pronounced anaemia developed within the first 3 months of treatment. The anaemia responded to dose-reduction while pressure control was maintained. Serial echocardiographic studies were performed. They illustrate the beneficial haemodynamic effects of captopril in the follow-up of children under antihypertensive treatment. Some recommendations are made on the use of captopril in children.

Citing Articles

Erythropoiesis and Blood Pressure Are Regulated via AT1 Receptor by Distinctive Pathways.

Kato H, Ishida J, Matsusaka T, Ishimaru T, Tanimoto K, Sugiyama F PLoS One. 2015; 10(6):e0129484.

PMID: 26107632 PMC: 4479565. DOI: 10.1371/journal.pone.0129484.

References

Lutkenhaus C, Bonzel K, DIEKMANN L, Koch H . [Successful treatment of renal hypertension in a 2 1/2-year-old girl with the converting enzyme inhibitor captopril (author's transl)]. Monatsschr Kinderheilkd. 1980; 128(11):724-6. View

Hodsman G, Isles C, Murray G, Usherwood T, Webb D, Robertson J . Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J (Clin Res Ed). 1983; 286(6368):832-4. PMC: 1547159. DOI: 10.1136/bmj.286.6368.832. View

Wenting G, Man int Veld A, Woittiez A, Boomsma F, Simoons M, Hugenholtz P . Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. Br Heart J. 1983; 49(1):65-76. PMC: 485212. DOI: 10.1136/hrt.49.1.65. View

Oberfield S, Case D, LEVINE L, Rapaport R, Rauh W, New M . Use of the oral angiotensin I--converting enzyme inhibitor (captopril) in childhood malignant hypertension. J Pediatr. 1979; 95(4):641-4. DOI: 10.1016/s0022-3476(79)80787-8. View

Vidt D, Bravo E, Fouad F . Drug therapy. Captopril. N Engl J Med. 1982; 306(4):214-9. DOI: 10.1056/NEJM198201283060405. View

Gavras I, Graff L, Rose B, McKenna J, Brunner H, Gavras H . Fatal pancytopenia associated with the use of captopril. Ann Intern Med. 1981; 94(1):58-9. DOI: 10.7326/0003-4819-94-1-58. View

FOLKOW B, Hallback M, Lundgren Y, SIVERTSSON R, WEISS L . Importance of adaptive changes in vascular design for establishment of primary hypertension, studied in man and in spontaneously hypertensive rats. Circ Res. 1973; 32:Suppl 1:2-16. DOI: 10.1007/978-3-642-65441-1_23. View

Hymes L, Warshaw B . Captopril. Long-term treatment of hypertension in a preterm infant and in older children. Am J Dis Child. 1983; 137(3):263-6. View

Mimran A, Jover B . Maintenance of the antihypertensive efficacy of captopril despite consistent reduction in daily dosage. Br J Clin Pharmacol. 1982; 14 Suppl 2:81S-85S. PMC: 1427506. DOI: 10.1111/j.1365-2125.1982.tb02062.x. View

10.

Hricik D, Browning P, Kopelman R, Goorno W, Madias N, Dzau V . Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983; 308(7):373-6. DOI: 10.1056/NEJM198302173080706. View

11.

Amann F, Buhler F, Conen D, Brunner F, Ritz R, Speck B . Captoril-associated agranulocytosis. Lancet. 1980; 1(8160):150. View

12.

Weinberger M . Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension. Br J Clin Pharmacol. 1982; 14 Suppl 2:127S-131S. PMC: 1427520. DOI: 10.1111/j.1365-2125.1982.tb02069.x. View

13.

Staessen J, Fagard R, Lijnen P, Amery A . Captopril and agranulocytosis. Lancet. 1980; 1(8174):926-7. DOI: 10.1016/s0140-6736(80)90853-3. View

14.

Monnens L, Drayer J, de Jong M . Malignant hypertension in a child with hemolytic-uremic syndrome treated with captopril. Acta Paediatr Scand. 1981; 70(4):583-5. DOI: 10.1111/j.1651-2227.1981.tb05747.x. View

15.

Dombey S . Optimal dose of captopril in hypertension. Lancet. 1983; 1(8323):529. DOI: 10.1016/s0140-6736(83)92216-x. View

16.

Friedman A, Chesney R, Ball D, GOODFRIEND T . Effective use of captopril (angiotensin I-converting enzyme inhibitor) in severe childhood hypertension. J Pediatr. 1980; 97(4):664-7. DOI: 10.1016/s0022-3476(80)80038-2. View

17.

van Brummelen P, Willemze R, Tan W, Thompson J . Captopril-associated agranulocytosis. Lancet. 1980; 1(8160):150. DOI: 10.1016/s0140-6736(80)90629-7. View

18.

Havelka J, Boerlin H, Studer A, Greminger P, Tenschert W, Luescher T . Long-term experience with captopril in severe hypertension. Br J Clin Pharmacol. 1982; 14 Suppl 2:71S-76S. PMC: 1427525. DOI: 10.1111/j.1365-2125.1982.tb02060.x. View

19.

DUSTAN H, PAGE I, TARAZI R, Frohlich E . Arterial pressure responses to discontinuing antihypertensive drugs. Circulation. 1968; 37(3):370-9. DOI: 10.1161/01.cir.37.3.370. View

20.

Matson J, Norby L, Robillard J . Interaction of minoxidil and captopril in the treatment of refractory hypertension. Am J Dis Child. 1981; 135(3):256-8. DOI: 10.1001/archpedi.1981.02130270048016. View